MAPT and early-onset autosomal dominant Alzheimer disease: However, using this cohort, we cannot ascertain that amyloid-/tau-negative individuals who are glycan positive later develop Alzheimer’s disease–related pathology, since no longitudinal data on amyloid/tau status are available and no samples from patients with other neurodegenerative diseases were analysed.